TGFB1 and metabolic dysfunction-associated steatotic liver disease: Herein, promising therapeutic approaches were aroused, such as the TNFα/TNFR1 axis blockage to prevent NAFLD progression, anti-TGF-β therapy to alleviate liver fibrosis or neutralization of IFNγ activity to revert both liver inflammation and injury.